Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines



   syncope
  

Disease ID 1114
Disease syncope
Definition
A transient loss of consciousness and postural tone caused by diminished blood flow to the brain (i.e., BRAIN ISCHEMIA). Presyncope refers to the sensation of lightheadedness and loss of strength that precedes a syncopal event or accompanies an incomplete syncope. (From Adams et al., Principles of Neurology, 6th ed, pp367-9)
Synonym
[d]: [fainting] or [collapse]
[d]: [fainting] or [collapse] (disorder)
[d]: [fainting] or [collapse] (situation)
[d]fainting
[d]fainting (context-dependent category)
[d]fainting (situation)
[d]syncope
[d]syncope and collapse
[d]syncope and collapse (context-dependent category)
[d]syncope and collapse (situation)
[d]syncope and collapse nos
[d]syncope and collapse nos (context-dependent category)
[d]syncope and collapse nos (situation)
a faint
attacks fainting
attacks syncopal
collapse [d]
collapse fleeting
collapse syncope
collapse transient
disorders syncope
faint
faint symptom
fainted
fainting
fainting (finding)
fainting [d]
fainting attacks
fainting episodes
fainting syncope
fainting/syncope
faintness
faints
falling out
falls out
out pass
out passed
out passes
pass out
passed out
swoon
swooning
swoons
syncope (disorder)
syncope (finding)
syncope [disease/finding]
syncope and collapse
syncope and collapse (disorder)
syncope attack
syncope collapse
syncope fainting
syncope symptom
syncope symptom (disorder)
syncope, nos
syncopes
ICD10
UMLS
C0039070
MeSH
SNOMED-CT
Comorbidity
UMLS | Disease | Sentences' Count(Total Sentences:75)
C1142166  |  brugada syndrome  |  9
C0018799  |  heart disease  |  9
C0878544  |  cardiomyopathy  |  5
C0014544  |  epilepsy  |  4
C0004245  |  atrioventricular block  |  3
C0149931  |  migraine  |  3
C0242379  |  lung cancer  |  3
C0010068  |  coronary artery disease  |  3
C0014556  |  temporal lobe epilepsy  |  3
C0003507  |  aortic valve stenosis  |  2
C0002624  |  retrograde amnesia  |  2
C0034065  |  pulmonary embolism  |  2
C0011570  |  depression  |  2
C0020538  |  hypertension  |  2
C0020598  |  hypoglycemia  |  2
C0349788  |  arrhythmogenic right ventricular cardiomyopathy  |  2
C0006384  |  bundle branch block  |  2
C0154731  |  glossopharyngeal neuralgia  |  2
C0497327  |  dementia  |  2
C0007194  |  hypertrophic cardiomyopathy  |  2
C0013384  |  abnormal movements  |  1
C0268407  |  cardiac amyloidosis  |  1
C0020598  |  hypoglycaemia  |  1
C0494165  |  hepatic metastases  |  1
C0027765  |  neurologic disorders  |  1
C0014544  |  epileptic seizure  |  1
C0003507  |  aortic stenosis  |  1
C0027765  |  neurologic disorder  |  1
C0036421  |  systemic sclerosis  |  1
C0040053  |  thrombus  |  1
C0031511  |  phaeochromocytoma  |  1
C0156273  |  bladder diverticulum  |  1
C0155626  |  acute myocardial infarction  |  1
C0149925  |  small cell lung cancer  |  1
C0024899  |  mastocytosis  |  1
C0376670  |  alcoholic pancreatitis  |  1
C0013384  |  abnormal movement  |  1
C0221013  |  systemic mastocytosis  |  1
C0042568  |  vertebrobasilar insufficiency  |  1
C0018799  |  heart diseases  |  1
C0027765  |  neurological disorder  |  1
C0011860  |  type 2 diabetes  |  1
C0014544  |  epileptic seizures  |  1
C0024141  |  systemic lupus erythematosus  |  1
C0458219  |  complex regional pain syndrome  |  1
C0037198  |  sinus thrombosis  |  1
C0027809  |  schwannoma  |  1
C0027765  |  neurological disease  |  1
C0022116  |  ischemia  |  1
C0032285  |  pneumonia  |  1
C0018801  |  heart failure  |  1
C0014733  |  erysipelas  |  1
C0020676  |  hypothyroidism  |  1
C0549473  |  thyroid carcinoma  |  1
C0042373  |  vascular disease  |  1
C0024299  |  lymphoma  |  1
C0023976  |  long qt syndrome  |  1
C0027051  |  myocardial infarction  |  1
C0018799  |  cardiac disease  |  1
C0040053  |  thrombosis  |  1
C0042075  |  urological diseases  |  1
C0011847  |  diabetes  |  1
C1619734  |  pulmonary arterial hypertension  |  1
C0007222  |  cardiovascular disease  |  1
C0003467  |  anxiety  |  1
C0264832  |  peripartum cardiomyopathy  |  1
C0007115  |  thyroid ca  |  1
C0027051  |  myocardial infarct  |  1
C0039263  |  takayasu's disease  |  1
C1631597  |  catecholaminergic polymorphic ventricular tachycardia  |  1
C0151740  |  intracranial hypertension  |  1
C0038531  |  subclavian steal syndrome  |  1
C0027947  |  neutropenia  |  1
C0238463  |  papillary thyroid carcinoma  |  1
C0043202  |  wolff-parkinson-white syndrome  |  1
Curated Gene(Waiting for update.)
Inferring Gene
Entrez_id | Symbol | Resource(Total Genes:3)
135  |  ADORA2A  |  infer
153  |  ADRB1  |  infer
5997  |  RGS2  |  infer
Text Mined Gene(Waiting for update.)
Locus(Waiting for update.)
Disease ID 1114
Disease syncope
Integrated Phenotype(Waiting for update.)
Text Mined Phenotype
HPO | Name | Sentences' Count(Total Phenotypes:100)
HP:0011675  |  Arrhythmias  |  21
HP:0002615  |  Low blood pressure  |  16
HP:0002527  |  Falls  |  11
HP:0001649  |  Tachycardia  |  11
HP:0012531  |  Pain  |  11
HP:0007185  |  Loss of consciousness  |  10
HP:0012668  |  Situational syncope  |  8
HP:0001962  |  Palpitations  |  7
HP:0001278  |  Orthostatic hypotension  |  7
HP:0001250  |  Seizures  |  7
HP:0004756  |  Ventricular tachycardia  |  6
HP:0012735  |  Coughing  |  6
HP:0100749  |  Thoracic pain  |  6
HP:0005110  |  Atrial fibrillation  |  5
HP:0001638  |  Cardiomyopathy  |  5
HP:0002315  |  Headaches  |  5
HP:0012173  |  Postural tachycardia  |  4
HP:0001662  |  Bradycardia  |  4
HP:0012722  |  Heart block  |  4
HP:0001663  |  Ventricular fibrillation  |  4
HP:0004308  |  Ventricular arrhythmia  |  4
HP:0001650  |  Valvular aortic stenosis  |  3
HP:0002076  |  Migraine headaches  |  3
HP:0001664  |  Torsade de pointes  |  3
HP:0001678  |  Atrioventricular block  |  3
HP:0001677  |  Coronary artery disease  |  3
HP:0000975  |  Increased sweating  |  3
HP:0001943  |  Hypoglycemia  |  3
HP:0001695  |  Cardiac arrest  |  3
HP:0001709  |  Complete heart block  |  2
HP:0001657  |  Prolonged QT interval  |  2
HP:0002204  |  Pulmonary embolism  |  2
HP:0000961  |  Cyanosis  |  2
HP:0001639  |  Hypertrophic cardiomyopathy  |  2
HP:0011710  |  Bundle-branch block  |  2
HP:0000716  |  Depression  |  2
HP:0001712  |  Left ventricular hypertrophy  |  2
HP:0002617  |  Aneurysmal dilatation  |  2
HP:0001907  |  Thromboembolic disease  |  2
HP:0012378  |  Fatigue  |  2
HP:0002459  |  Dysautonomia  |  2
HP:0000822  |  Hypertension  |  2
HP:0000726  |  Dementia  |  2
HP:0004309  |  Pre-excitation syndrome  |  2
HP:0002890  |  Thyroid carcinoma  |  1
HP:0030731  |  Carcinoma  |  1
HP:0002090  |  Pneumonia  |  1
HP:0001944  |  Dehydration  |  1
HP:0002573  |  Bloody diarrhea  |  1
HP:0100495  |  Mastocytosis  |  1
HP:0002664  |  Neoplasia  |  1
HP:0010775  |  Vascular ring  |  1
HP:0001297  |  Cerebral vascular events  |  1
HP:0012417  |  Hypocapnia  |  1
HP:0002725  |  Systemic lupus erythematosus  |  1
HP:0001324  |  Muscular weakness  |  1
HP:0004754  |  Permanent atrial fibrillation  |  1
HP:0002063  |  Muscle rigidity  |  1
HP:0004749  |  Atrial flutter  |  1
HP:0001945  |  Fever  |  1
HP:0002647  |  Aortic dissection  |  1
HP:0030828  |  Wheezing  |  1
HP:0002018  |  Nausea  |  1
HP:0002248  |  Vomitting blood  |  1
HP:0003270  |  Distended abdomen  |  1
HP:0000622  |  Blurred vision  |  1
HP:0000821  |  Underactive thyroid  |  1
HP:0005184  |  Prolonged QTc interval  |  1
HP:0000739  |  Anxiety  |  1
HP:0030357  |  Small cell lung carcinoma  |  1
HP:0011663  |  Cardiomyopathy, right ventricular  |  1
HP:0012382  |  Left-to-right shunt  |  1
HP:0012669  |  Carotid sinus syncope  |  1
HP:0030833  |  Neck pain  |  1
HP:0001279  |  Syncope  |  1
HP:0000015  |  Bladder diverticula  |  1
HP:0100008  |  Schwann cell tumour  |  1
HP:0005115  |  arrhythmias, Supraventricular  |  1
HP:0030843  |  Cardiac amyloidosis  |  1
HP:0002895  |  Papillary thyroid carcinoma  |  1
HP:0012223  |  Ruptured spleen  |  1
HP:0002104  |  Absence of spontaneous respiration  |  1
HP:0001055  |  Erysipelas  |  1
HP:0002516  |  Intracranial pressure elevation  |  1
HP:0002094  |  Dyspnea  |  1
HP:0002524  |  Cataplexy  |  1
HP:0001716  |  Wolff-Parkinson-White syndrome  |  1
HP:0001714  |  Ventricular hypertrophy  |  1
HP:0001635  |  Congestive heart failure  |  1
HP:0006702  |  Spontaneous coronary artery dissection  |  1
HP:0002321  |  Vertigo  |  1
HP:0001289  |  Confusion  |  1
HP:0002249  |  Melena  |  1
HP:0100520  |  Oliguria  |  1
HP:0002027  |  Abdominal pain  |  1
HP:0002917  |  Low blood magnesium levels  |  1
HP:0002140  |  Ischemic stroke  |  1
HP:0001658  |  Myocardial infarction  |  1
HP:0001875  |  Neutropenia  |  1
HP:0002665  |  Lymphoma  |  1
Disease ID 1114
Disease syncope
Manually Symptom(Waiting for update.)
Text Mined Symptom
UMLS | Name | Sentences' Count(Total Symptoms:15)
C0020649  |  hypotension  |  13
C0039231  |  tachycardia  |  11
C0232197  |  fibrillation  |  9
C0008031  |  chest pain  |  5
C1720983  |  channelopathy  |  5
C0018794  |  heart block  |  4
C0006384  |  bundle branch block  |  2
C0154731  |  glossopharyngeal neuralgia  |  2
C0042420  |  vagal reaction  |  2
C0743841  |  febrile illness  |  1
C0007859  |  neck pain  |  1
C0018799  |  cardiac disease  |  1
C0003507  |  aortic stenosis  |  1
C0155626  |  acute myocardial infarction  |  1
C0015672  |  fatigue  |  1
Manually Genotype(Total Text Mining Genotypes:0)
(Waiting for update.)
All Snps(Total Genotypes:14)
snpId pubmedId geneId geneSymbol diseaseId sourceId sentence score Year geneSymbol_dbSNP CHROMOSOME POS REF ALT
rs104894585175824333759KCNJ2umls:C0039070BeFreeIn this study, we characterized the KCNJ2 channels with an ATS mutation (T75M) which is associated with cardiac phenotypes of bi-directional ventricular tachycardia, syncope, and QT(c) prolongation.0.0005428842007KCNJ21770175263CG,T
rs120074193164366353784KCNQ1umls:C0039070BeFreeAlthough G269S in the KVLQT1 gene was detected in a female with known family history of syncope and sudden cardiac death, no other mutations were found in any of the 14 cases, and no other mutations was found in 200 controls.0.0096200182006KCNQ1112572870GA,C
rs121434500185916646640SNTA1umls:C0039070BeFreeA missense mutation (A390V-SNTA1) was found in a patient with recurrent syncope and markedly prolonged QT interval (QTc, 530 ms).0.0005428842008SNTA12033410203GA
rs139467962233768256640SNTA1umls:C0039070BeFreeA Caucasian family with syncope and marginally prolonged QT interval was screened for LQTS-susceptibility genes and found to harbor the R800L mutation in SCN5A and A261V mutation in SNTA1, and those with both mutations had the strongest clinical phenotype.0.0005428842013SNTA12033412702GA
rs139467962233768256331SCN5Aumls:C0039070BeFreeA Caucasian family with syncope and marginally prolonged QT interval was screened for LQTS-susceptibility genes and found to harbor the R800L mutation in SCN5A and A261V mutation in SNTA1, and those with both mutations had the strongest clinical phenotype.0.0037242412013SNTA12033412702GA
rs18051232183196010238DCAF7umls:C0039070BeFreeSubgroup analysis showed that the presence of the K897T polymorphism in the LQT2 gene in an affected family was associated with an 11-fold (P=0.001) increase in the risk of recurrent syncope in genotype-negative subjects.0.0008143262011KCNH27150948446TG,A
rs1805123218319603757KCNH2umls:C0039070BeFreeSubgroup analysis showed that the presence of the K897T polymorphism in the LQT2 gene in an affected family was associated with an 11-fold (P=0.001) increase in the risk of recurrent syncope in genotype-negative subjects.0.0071770412011KCNH27150948446TG,A
rs199472718227087203784KCNQ1umls:C0039070BeFreeScreening KCNQ1, KCNH2, and SCN5A genes in the proband, who presented with syncope, led to the identification of a heterozygous mutation (p.H258P) in KCNQ1.0.0096200182012KCNQ1112572102AC,G
rs199472756230000223784KCNQ1umls:C0039070BeFreePrior clinical reports revealed phenotypic variability ranging from the absence of symptoms to syncope among KCNQ1 G325R mutation carriers.0.0096200182012KCNQ1112583486GA
rs199472823214592853784KCNQ1umls:C0039070BeFreeA novel KCNQ1 variant (L203P) associated with torsades de pointes-related syncope in a Steinert syndrome patient.0.0096200182011KCNQ1112571328TC
rs199473012186752273757KCNH2umls:C0039070BeFreeThe patient affected by L955V suffered from recurrent syncope (QTc approximately 460 ms), and this mutation led to greatly reduced current and reduced KCNH2 protein in plasma membrane preparations.0.0071770412008KCNH27150947708GC
rs199473401124422763784KCNQ1umls:C0039070BeFreeInderal or propanolol (a beta blocker) appears to be effective in preventing arrhythmias and syncope for an LQTS patient with the KCNQ1 L191P mutation.0.0096200182002KCNQ1112570722TC
rs199473605196480626331SCN5Aumls:C0039070BeFreeA novel SCN5A missense mutation, V1340I, was identified in a patient with BrS suffering from frequent episodes of polymorphic ventricular tachycardia (VT) and syncope associated with fever.0.0037242412009SCN5A338560374CT
rs7626962124712056331SCN5Aumls:C0039070BeFreeIn this study, we define an SCN5A mutation, S1103Y, in a white family associated with syncope, ventricular fibrillation, and sudden death.0.0037242412002SCN5A338579416GA,T
GWASdb Annotation(Total Genotypes:0)
(Waiting for update.)
GWASdb Snp Trait(Total Genotypes:0)
(Waiting for update.)
Mapped by lexical matching(Total Items:0)
(Waiting for update.)
Mapped by homologous gene(Total Items:0)
(Waiting for update.)
Chemical(Total Drugs:53)
CUI ChemicalName ChemicalID CasRN DiseaseName DiseaseID DirectEvidence PubMedIDs
C0039070aminocaproic acidD01511960-32-2syncopeMESH:D013575marker/mechanism3951807
C0039070amitriptylineD00063950-48-6syncopeMESH:D013575marker/mechanism11144697
C0039070amlodipineD01731188150-42-9syncopeMESH:D013575marker/mechanism11966675
C0039070atenololD00126229122-68-7syncopeMESH:D013575marker/mechanism18613249
C0039070atenololD00126229122-68-7syncopeMESH:D013575therapeutic14727996
C0039070atropineD00128551-55-8syncopeMESH:D013575therapeutic7056119
C0039070bendroflumethiazideD00153973-48-3syncopeMESH:D013575marker/mechanism17452686
C0039070betaxololD01578463659-18-7syncopeMESH:D013575marker/mechanism8296748
C0039070caffeineD0021101958/8/2syncopeMESH:D013575marker/mechanism10337936
C0039070carbamazepineD002220298-46-4syncopeMESH:D013575marker/mechanism1148068
C0039070carbenicillinD0022284697-36-3syncopeMESH:D013575marker/mechanism4638000
C0039070chloroquineD0027381954/5/7syncopeMESH:D013575marker/mechanism11966675
C0039070chlorpromazineD00274650-53-3syncopeMESH:D013575marker/mechanism3530167
C0039070ciprofloxacinD00293985721-33-1syncopeMESH:D013575marker/mechanism15851230
C0039070cisaprideD02011781098-60-4syncopeMESH:D013575marker/mechanism12075394
C0039070citalopramD01528359729-33-8syncopeMESH:D013575marker/mechanism10958266
C0039070clonidineD0030004205-90-7syncopeMESH:D013575marker/mechanism261849
C0039070clonidineD0030004205-90-7syncopeMESH:D013575therapeutic12442198
C0039070clozapineD0030245786-21-0syncopeMESH:D013575marker/mechanism10520983
C0039070disopyramideD0042063737/9/5syncopeMESH:D013575marker/mechanism463780
C0039070doxycyclineD004318564-25-0syncopeMESH:D013575marker/mechanism9145823
C0039070enalaprilD00465675847-73-3syncopeMESH:D013575marker/mechanism10406995
C0039070esmololC03660484057-94-3syncopeMESH:D013575therapeutic8985804
C0039070fluconazoleD01572586386-73-4syncopeMESH:D013575marker/mechanism11144697
C0039070fluoxetineD00547354910-89-3syncopeMESH:D013575marker/mechanism11805215
C0039070haloperidolD00622052-86-8syncopeMESH:D013575marker/mechanism9120531
C0039070hydroxyzineD00691968-88-2syncopeMESH:D013575marker/mechanism19057127
C0039070labetalolD00774136894-69-6syncopeMESH:D013575marker/mechanism6844370
C0039070lidocaineD008012137-58-6syncopeMESH:D013575therapeutic4635436
C0039070loratadineD01733679794-75-5syncopeMESH:D013575marker/mechanism12698686
C0039070meprobamateD00862057-53-4syncopeMESH:D013575marker/mechanism5092569
C0039070methadoneD00869176-99-3syncopeMESH:D013575marker/mechanism14556883
C0039070metoprololD00879037350-58-6syncopeMESH:D013575therapeutic19353679
C0039070midodrineD00887942794-76-3syncopeMESH:D013575therapeutic14727996
C0039070nevirapineD019829129618-40-2syncopeMESH:D013575marker/mechanism18361857
C0039070nitroprussideD00959915078-28-1syncopeMESH:D013575marker/mechanism1628477
C0039070nortriptylineD00966172-69-5syncopeMESH:D013575marker/mechanism15669899
C0039070olanzapineC076029132539-06-1syncopeMESH:D013575marker/mechanism12095078
C0039070phenylephrineD01065659-42-7syncopeMESH:D013575marker/mechanism12528876
C0039070phenylpropanolamineD01066514838-15-4syncopeMESH:D013575marker/mechanism9853729
C0039070prazosinD01122419216-56-9syncopeMESH:D013575marker/mechanism7061132
C0039070propranololD011433525-66-6syncopeMESH:D013575marker/mechanism1879988
C0039070propranololD011433525-66-6syncopeMESH:D013575therapeutic15028050
C0039070quinineD011803130-95-0syncopeMESH:D013575marker/mechanism9604078
C0039070ramiprilD01725787333-19-5syncopeMESH:D013575marker/mechanism18378520
C0039070ribavirinD01225436791-04-5syncopeMESH:D013575marker/mechanism12197842
C0039070sotalolD0130153930-20-9syncopeMESH:D013575marker/mechanism6197982
C0039070tenofovirD000068698-syncopeMESH:D013575marker/mechanism18361857
C0039070terfenadineD01659350679-08-8syncopeMESH:D013575marker/mechanism8213879
C0039070thalidomideD01379250-35-1syncopeMESH:D013575marker/mechanism18613249
C0039070timololD01399926839-75-8syncopeMESH:D013575marker/mechanism16627515
C0039070tretinoinD014212302-79-4syncopeMESH:D013575marker/mechanism10609785
C0039070valproic acidD01463599-66-1syncopeMESH:D013575marker/mechanism12057805
FDA approved drug and dosage information(Total Drugs:11)
DiseaseID Drug_name active_ingredients strength Dosage Form/Route Marketing Status TE code RLD RS
MESH:D013575claritinloratadine10MGTABLET;ORALOver-the-counterNoneYesYes
MESH:D013575claritinloratadine1MG/MLSYRUP;ORALOver-the-counterNoneYesYes
MESH:D013575claritinloratadine10MGCAPSULE;ORALOver-the-counterNoneYesYes
MESH:D013575loratadineloratadine10MGTABLET;ORALDiscontinuedNoneNoNo
MESH:D013575loratadineloratadine1MG/MLSUSPENSION;ORALOver-the-counterNoneYesYes
MESH:D013575ciprociprofloxacin400MG/40ML (10MG/ML)INJECTABLE;INJECTIONDiscontinuedNoneYesNo
MESH:D013575ciprociprofloxacin250MG/5MLFOR SUSPENSION;ORALPrescriptionABYesNo
MESH:D013575zyprexaolanzapine2.5MGTABLET;ORALPrescriptionABYesNo
MESH:D013575zyprexaolanzapine10MG/VIALINJECTABLE;INTRAMUSCULARPrescriptionAPYesYes
MESH:D013575zyprexaolanzapine2.5MGTABLET;ORALPrescriptionABYesNo
MESH:D013575zyprexaolanzapine10MG/VIALINJECTABLE;INTRAMUSCULARPrescriptionAPYesYes
FDA labeling changes(Total Drugs:11)
DiseaseID Pediatric_Labeling_Date Trade_Name Generic_Name_or_Proper_Name Indications Studied Label Changes Summary Product Labeling BPCA(B) PREA(P) BPCA(B) and PREA(P) Pediatric Rule (R) Sponsor Pediatric Exclusivity Granted Date NNPS
MESH:D0135754/12/2000claritinloratadineAllergic rhinitis/UrticariaLabeling for 2 - 5 year olds including information on dose, PK parameters and AE profile PK parameter in 2-5 year olds given a 5mg dose was comparable to the 10mg dose in children 6 years to adolescenceLabelingB---Schering08/14/2000FALSE'
MESH:D0135754/12/2000claritinloratadineAllergic rhinitis/UrticariaLabeling for 2 - 5 year olds including information on dose, PK parameters and AE profile PK parameter in 2-5 year olds given a 5mg dose was comparable to the 10mg dose in children 6 years to adolescenceLabelingB---Schering08/14/2000FALSE'
MESH:D0135754/12/2000claritinloratadineAllergic rhinitis/UrticariaLabeling for 2 - 5 year olds including information on dose, PK parameters and AE profile PK parameter in 2-5 year olds given a 5mg dose was comparable to the 10mg dose in children 6 years to adolescenceLabelingB---Schering08/14/2000FALSE'
MESH:D0135754/12/2000claritinloratadineAllergic rhinitis/UrticariaLabeling for 2 - 5 year olds including information on dose, PK parameters and AE profile PK parameter in 2-5 year olds given a 5mg dose was comparable to the 10mg dose in children 6 years to adolescenceLabelingB---Schering08/14/2000FALSE'
MESH:D0135754/12/2000claritinloratadineAllergic rhinitis/UrticariaLabeling for 2 - 5 year olds including information on dose, PK parameters and AE profile PK parameter in 2-5 year olds given a 5mg dose was comparable to the 10mg dose in children 6 years to adolescenceLabelingB---Schering08/14/2000FALSE'
MESH:D01357503/25/2004ciprociprofloxacinComplicated UTI and pyelonephritisIndicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1  17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1  17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectivelyLabelingB---Bayer12/18/2003FALSE'
MESH:D01357503/25/2004ciprociprofloxacinComplicated UTI and pyelonephritisIndicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1  17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1  17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectivelyLabelingB---Bayer12/18/2003FALSE'
MESH:D01357508/14/2008zyprexaolanzapineschizophrenia; bipolar disorderSafety and effectiveness have not been established for patients less than 18 years of age In an analysis of placebo-controlled olanzapine monotherapy studies of adolescent patients, including those with schizophrenia or bipolar disorder, olanzapine was associated with: oHyperglycemia - a statistically significantly greater mean change in fasting glucose levels compared to placebo oHyperlipidemia  statistically significant increases compared to placebo in fasting triglycerides, fasting total cholesterol and fasting LDL cholesterol oWeight gain  olanzapine treated patients gained an average of 4.6 kg, compared to an average of 0.3 kg in placebo-treated patients with a median exposure of 3 weeks; Average weight gain during long-term therapy was 7.4 kg-B---Lilly10/1/2007FALSE'
MESH:D01357508/14/2008zyprexaolanzapineschizophrenia; bipolar disorderSafety and effectiveness have not been established for patients less than 18 years of age In an analysis of placebo-controlled olanzapine monotherapy studies of adolescent patients, including those with schizophrenia or bipolar disorder, olanzapine was associated with: oHyperglycemia - a statistically significantly greater mean change in fasting glucose levels compared to placebo oHyperlipidemia  statistically significant increases compared to placebo in fasting triglycerides, fasting total cholesterol and fasting LDL cholesterol oWeight gain  olanzapine treated patients gained an average of 4.6 kg, compared to an average of 0.3 kg in placebo-treated patients with a median exposure of 3 weeks; Average weight gain during long-term therapy was 7.4 kg-B---Lilly10/1/2007FALSE'
MESH:D0135754/12/2009zyprexaolanzapineTreatment of manic or mixed episodes of bipolar I disorder and schizophrenia in adolescents ages 13-17Extended schizophrenia and manic or mixed episodes of bipolar I disorder indications from adults to adolescents 1317 years of age Safety and effectiveness in children < 13 years of age have not been established Recommended starting dose for adolescents is lower than that for adults Compared to patients from adult clinical trials, adolescents were likely to gain more weight, experience increased sedation, and have greater increases in total cholesterol, triglycerides, LDL cholesterol, prolactin and hepatic transaminase levels Information on dosing, adverse reactions, pharmacokinetics, clinical studiesLabelingB---Lilly10/1/2007TRUE'
MESH:D0135754/12/2009zyprexaolanzapineTreatment of manic or mixed episodes of bipolar I disorder and schizophrenia in adolescents ages 13-17Extended schizophrenia and manic or mixed episodes of bipolar I disorder indications from adults to adolescents 1317 years of age Safety and effectiveness in children < 13 years of age have not been established Recommended starting dose for adolescents is lower than that for adults Compared to patients from adult clinical trials, adolescents were likely to gain more weight, experience increased sedation, and have greater increases in total cholesterol, triglycerides, LDL cholesterol, prolactin and hepatic transaminase levels Information on dosing, adverse reactions, pharmacokinetics, clinical studiesLabelingB---Lilly10/1/2007TRUE'